Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome

NCT01201837 is registered in ClinicalTrials.gov with Cerenis Therapeutics, SA as lead sponsor.

NCT NCT01201837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01201837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome
Lead sponsor
Cerenis Therapeutics, SA
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
March 31, 2013
Enrollment
507 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome